In this free webinar, learn how artificial intelligence (AI) can augment and empower humans to make better quality decisions in R&D, leading to improved clinical attrition. Attendees will learn about the impact of clinical attrition, and the reasons why it is so high. The featured speakers will discuss how AI can read and digest information from millions of biomedical documents, extract key insights and present researchers with a complete view of the data. Attendees will also learn how integrating AI into key points in the R&D value chain can improve decision-making and lower attrition — thus saving huge amounts of time and money.
TORONTO, Sept. 22, 2022 /PRNewswire-PRWeb/ -- This webinar will illustrate how technology can ensure researchers get a thorough, bird's eye view of all available evidence, enabling faster, better-informed decisions from target identification through to Phase III clinical trials. This decreases clinical attrition, saves businesses a huge amount of time and money and ultimately brings more lifesaving medicines to market.
It is well documented that only 10 percent of clinical candidates make it to market. This is a startlingly low figure, especially when millions of dollars and years of development that go into a single candidate are taken into consideration.
The reasons for failure are known, with one of the most critical being poor target validation in the early stages of drug development. It has been shown that success rates increase when better informed decisions are made early on. To improve clinical attrition, it is therefore imperative to improve decision-making in R&D.
Artificial Intelligence (AI) has been transformative for many industries such as banking, automotive and transportation. Drug development however has not been impacted to the same degree. This is in part due to the drug development process being lengthy and complex, making it inherently difficult to integrate innovations. However, by using AI to influence key decision points along the R&D value chain, it is possible to unlock technology's real value.
Register to learn how AI can augment and empower humans to make better quality decisions in R&D, leading to improved clinical attrition.
Join Yiannis Kiachopoulos, Co-Founder & CEO, Causaly; Richard Harrison, Chief Scientist, Causaly; Mike Rea, Chief Executive Officer, IDEA Pharma; and Partha Ghosh, Head of Consulting, IDEA Pharma, for the live webinar on Wednesday, October 12, 2022, at 10am EDT (3pm BST/UK).
For more information, or to register for this event, visit Improving Clinical Attrition and Decision-Making with Artificial Intelligence.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, firstname.lastname@example.org
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.